Phenomenological screening of small molecule libraries for anticancer activity yields potentially interesting candidate molecules, with a bottleneck in the determination of drug targets and the mechanism of anticancer action. A novel approach to drug target deconvolution compares the abundance profiles of proteins expressed in a panel of cells treated with different drugs, and identifies proteins with cell-type independent and drug-specific regulation that is exceptionally strong in relation to the other proteins. Mapping top candidates on known protein networks reveals the mechanism of drug action, while abundant proteins provide a signature of cellular death/survival pathways. The above approach can significantly shorten drug target identification, and thus facilitate the emergence of novel anticancer treatments.
Target-directed discovery is the way pharmaceutical industry most often uses in searching for new drugs, with compound libraries screened for binding or activity against a known protein target. In contrast, phenomenological screening of small molecule libraries is a "black-box" target-agnostic approach, where compounds are interrogated in cell-based assays with a readout linked to a disease-relevant process (e.g. cancer cell apoptosis). Arguably, this latter approach to drug discovery offers better chances for success because more targets are addressed and the assay is more relevant to human physiology. Indeed, between 1999 and 2008, of the first-in-class compounds that were approved by the FDA, only 38% had been derived from targetbased screening, while the rest -from phenotypic screening. 1 However efficient, phenomenological screening has a serious bottleneck in drug target discovery and validation. Less than 200 small-molecule anticancer drugs approved by FDA have a known mechanism of action, while thousands of promising molecules remain with poorly known or unknown targets. 2, 3 This mismatch between the number of promising compounds and the knowledge of the targets and underlying mechanisms of action represents one of the greatest unmet needs in war against cancer.
Mass-spectrometry based proteomics is a well established tool in drug discovery. 4 Unlike transcriptomics that covers the whole range of expressed genes, a typical untargeted 1D LC-MS/MS proteomics experiment can detect and quantify up to 5,000 proteins, which is less than half of the expressed human proteome. 5 However, proteomics technology rapidly progresses, and deep proteome analysis with more than 8,000 protein groups quantified is becoming increasingly available. [6] [7] [8] [9] Besides, measuring relative protein concentrations accounts not only for protein expression but also for protein degradation, which makes proteomics particularly valuable in drug target discovery. Indeed, drug attachment often stabilizes the protein and makes it more resistant to degradation, which leads to protein target accummulation. 10, 11 Alternatively, drug-induced protein translocation from nucleus to cytoplasm can cause its rapid degradation. 12 Recently, significant hope has been associated with dynamic proteomics, which had a promising start in drug target discovery. In a landmark experiment (performed without the use of mass spectrometry), the known target for camptothecin, DNA topoisomerase 1 (TOP1), has been found among the proteins with fast and deep abundance reduction upon drug application. 12 However, detailed analysis of the dynamic proteomics data using time-dependent abundance changes as sole criteria could only identify TOP1 as the 35 th most likely candidate among ca. 900 quantified proteins. 13 This result epitomizes the main weakness of the dynamic proteomics approach to drug target discovery: while a multitude of proteins change their abundance upon drug application (in the cited experiment, all measured protein abundances have changed within 48 h), 12 many changes have low specificity in respect to the drug.
Therefore, appropriate filtering ("in silico target purification") is needed to disregard these unspecific proteins and identify the true drug target. Pathway analysis can provide such a filter; being applied to the dynamic proteomics dataset, it identified TOP1 together with only eight other likely candidates. 13 However, while of clearly significant potential for drug discovery, the pathway analysis approach has a number of shortcomings limiting its generality. Importantly, it searches targets among the known key nodes (bottleneck regulatory molecules) in the pathway database, relying on already known information for data filtering. In essence, only known potential drug targets will be discovered, with the discovery process being database-sensitive.
An alternative approach could be to focus on early times after drug applications. The rational is that the initial cellular response should be most drugspecific, while the late response (e.g., apoptosis) is largely generic. However, in an analysis 14 of early response times of RKO cells to a broadly used anticancer substance, 5-fluorouracil (5-FU), which has a well-known target, thymidylate synthase (TYMS), the changes in the first few hours past drug treatment have been too small to be measured with sufficient statistical confidence.
Recently, we have found that the apoptotic response is much less generic than has previously been thought, and that in fact proteome changes become more apparent and drug-specific in late apoptosis. Based on this finding, we have developed a new method of drug target identification that does not require a priori knowledge of signaling or metabolic pathways and has a high robustness. The method achieves in silico target purification using an expression proteomics dataset obtained from a treatment of a panel of cell lines ( 2 cell lines) with a panel of drugs ( 3 molecules).
The approach is based on the assumptions that the drug target significantly changes its abundance (up or down) in late apoptosis, and that the drug target abundance behaves similarly for different cell lines that are sensitive to the drug. It is understood that the validity of these assumptions will be a factor limiting the applicability of the approach; however, most systems tested so far complied with these assumptions. The method also capitalizes on recent developments in label-free proteomics 5, 15, 16 that made possible analysis of 5000 proteins in a reasonably short time (3-4 h Since starvation/senescence was included in the experiment, the proteomics dataset of this "natural environment" cell suppression could be processed in the same way as other datasets for drug-treated proteomes. In total, 91 proteins were found with p<0.01, much more than in any other treatment, which is consistent with many molecules being targeted by the toxic waste products accumulated in the media.
Among the top proteins, there are many known and prospective targets for anticancer therapy. For instance, thioredoxin (rank 3; downregulated) has been identified as a molecule of significant interest to chemotherapy 20 , while 3-hydroxyisobutyryl-CoA hydrolase (HIBCH) (upregulated; rank 6) is one of the targets for Quercetin, a molecule found in grape juice, which is being tested as a treatment of prostate cancer by diet (http://clinicaltrials.gov/ct2/show/NCT01912820). The most striking upregulation ( Figure 2c ) is shown by inter alpha-trypsin inhibitor heavy chain 2 (ITIH2, rank 1). ITIH2 has earlier been suggested to act as a tumor-suppressing protein. 21 We hypothesize that ITIH2 plays an important role in cancer cell survival at adverse conditions and thus represents a potential drug target. (target for CAMP) was on the 9 th position with p=1.1⋅10 -3 . For PCTL, the target ß-tubulin (TUBB8) was on the 7 th position (p=1.3⋅10 -3 ) out of 11 significant proteins (Supplementary Table 2 ). Therefore, even in this limited experiment with only two cell lines, the drug targets were confined to a small number (on average, nine) protein candidates.
Experiment III. To determine the minimal experiment that can provide meaningful data, we have treated HCT116 cells with 5-FU for 24 h in a triplicate and analyzed the extracted proteins against a triplicate control grown for the same time.
The experiment was repeated twice, one time using label-free quantification (3,800 proteins quantified), and another time -with TMT-10 quantification (4,800 proteins).
In the label-free dataset (median coefficient of variation of protein abundances among the biological replicates was CV 9%), the target TYMS was on the 28 th position in terms of absolute regulation, while in the TMT-10 dataset (CV 5% 
Discussion
Just a few years ago, cross-comparison of three cells lines at the baseline to the depth of 5,000 proteins has been reported for the first time. 23 Rapid recent progress in proteomics instrumentation and software have led to a marked decrease in the duration of a typical proteomics experiment, enabling analysis of 5,000 proteins in the time frame of 2 h. 16 This opened a previously unexplored opportunity to apply cellular proteomics to dozens, 8 comparing OPLS-DA scores of the A-set and S-set. was searched, with reversed protein sequences concatenated as a decoy for determining the false discovery rate (FDR).
TABLES
Quantitative information was extracted using in-house developed label-free Scoring system. For combining the data from replicate analysis, "medians of ratios" are used instead of "ratios of medians", as has previously been suggested. 24 If relative protein abundance of i-th quantified protein in c-th cell line under j-th treatment is denoted as , then regulation Reg is calculated as:
( 1) and specificity Spec is defined as:
where j=0 corresponds to untreated cells for Reg calculation, and j k for Spec calculations. p-value calculation. In estimation of the p-value of a protein with a certain rank, we used the rank product method, which has previously been found to be robust and tolerant to missing values in detection differentially regulated genes in replicated experiments. 25 The method has also been successfully applied to proteomics datasets for detection of significantly regulated proteins. 26 In adaptation of the method by 
